Bcl-2 expression in cell lines breast cancer and death program.

Area of Science:

• Oncology
• Molecular Biology
• Nanotechnology

Background:

• Breast cancer is a heterogeneous, hormone-dependent disease where drug resistance limits treatment efficacy.
• Combinatorial therapies and molecular approaches, including Bcl-2 inhibitors and ER blockers, show promise for improved recovery.
• Antisense oligonucleotides (ASOs) offer a strategy to inhibit gene expression, such as Bcl-2, potentially inducing cancer cell apoptosis.

Purpose of the Study:

• To design and evaluate a novel Antisense Oligonucleotide (ASO) based on G3139 for breast cancer treatment.
• To assess the efficacy of ASO and Tamoxifen, delivered via liposomes and cationic nano-complexes (Niosomes), in inhibiting cancer cell proliferation.
• To investigate the synergistic effects of ASO and Tamoxifen on breast cancer cells.

Main Methods:

• Design of a novel ASO targeting the Bcl-2 gene.
• Utilized MCF-7 and MDA-MB-231 breast cancer cell lines for proliferation assays.
• Employed liposomes and cationic nano-complexes (Niosomes) for enhanced cellular delivery of ASO and Tamoxifen.
• Assessed cytotoxicity and apoptosis using flow cytometry.

Main Results:

• The designed ASO significantly down-regulated Bcl-2 gene expression in breast cancer cells.
• Inhibition of MCF-7 and MDA-MB-231 cellular proliferation was observed.
• Flow cytometry confirmed early apoptosis induction across all treated cell groups.
• The ASO demonstrated a synergistic effect when combined with Tamoxifen.

Conclusions:

• The novel Bcl-2 ASO effectively reduces breast cancer cell proliferation and induces apoptosis.
• Cationic nano-complex (Niosome) delivery systems are more efficient for ASO and Tamoxifen than liposomes.
• This ASO holds potential as a targeted molecular therapy for breast cancer, especially in combination with Tamoxifen.